Back to Search
Start Over
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
- Source :
-
International journal of clinical oncology [Int J Clin Oncol] 2022 Dec; Vol. 27 (12), pp. 1874-1880. Date of Electronic Publication: 2022 Oct 10. - Publication Year :
- 2022
-
Abstract
- Background: Outcomes with and without bevacizumab as first-line chemotherapy in Japanese-only ovarian cancer patients have not been reported. In this study, we report a retrospective study conducted at the Tohoku Gynecologic Cancer Unit.<br />Patients and Methods: The study included 453 patients with stage III/IV ovarian, fallopian tube, and primary peritoneal cancer who received first-line platinum-based chemotherapy. The patients were divided into two groups: bevacizumab (168 patients) and without bevacizumab (285 patients). The primary endpoint was the rate of platinum-resistant recurrence and the secondary endpoints were the antitumor response, progression-free survival, overall survival, and adverse events.<br />Results: The objective response rates for patients with measurable diseases treated with and without bevacizumab were 84.5% and 73.0%, respectively (P = 0.0066). Platinum-resistant recurrence in the groups treated with and without bevacizumab was noted in 31 (18.4%) and 111 (38.6%) patients, respectively (P < 0.0001). The median progression-free survival for the bevacizumab and without bevacizumab groups was 23 and 15 months, respectively (P = 0.0002), and the median overall survival was not reached and 49 months, respectively (P = 0.0005). Hypertension of grade 3 or higher was observed in 21 patients (12.5%) in the bevacizumab group (P < 0.001), and proteinuria was observed in 18 patients (10.7%) and 1 patient (0.3%) in the bevacizumab and without bevacizumab groups, respectively (P < 0.001). Intestinal perforation was observed in only one patient (0.6%) in the bevacizumab group.<br />Conclusion: Combination and maintenance with bevacizumab in primary chemotherapy for advanced ovarian, fallopian tube, and primary peritoneal cancer was effective in reducing platinum-resistant recurrence rates and prolonging progression-free and overall survival.<br /> (© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.)
- Subjects :
- Humans
Female
Bevacizumab adverse effects
Fallopian Tubes pathology
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols adverse effects
Progression-Free Survival
Platinum adverse effects
Neoplasm Recurrence, Local pathology
Fallopian Tube Neoplasms drug therapy
Fallopian Tube Neoplasms pathology
Peritoneal Neoplasms pathology
Ovarian Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1437-7772
- Volume :
- 27
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- International journal of clinical oncology
- Publication Type :
- Academic Journal
- Accession number :
- 36214925
- Full Text :
- https://doi.org/10.1007/s10147-022-02246-1